Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab + Atezolizumab +/- Cobimetinib in Untreated Melanoma Brain Metastases
NCT03175432Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2017
- Primary completion
- Jun 2028
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in melanoma brain metastases (MBM) comparing Arm I (atezolizumab, bevacizumab) with Arm II (atezolizumab, bevacizumab, cobimetinib) (2 arms). Primary endpoints: Objective Intracranial Response Rate at 3 years and Safety, tolerability, and efficacy at 3 years. Started Jun 2017; status: active, not recruiting.
02
Drugs
atezolizumabbevacizumabcobimetinib
03
Conditions
melanoma brain metastases (MBM)
Beyond the preview
Go deeper on NCT03175432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03175432.